Chinese Thoracic Oncology Group (CTONG) and OrigiMed, a medical science and technology company, have unveiled a new clinical trial sharing platform to provide better clinical benefits for patients across the country.
The CTONG-OrigiMed platform will build on CTONG’s clinical experience and OrigiMed’s next generation sequencing expertise. It will offer information on different types of complex clinical cases.
This sharing cooperation is expected to facilitate better precision medicine clinical trials for cancer.
OrigiMed CEO Dr Kai Wang said: “With more genes sequenced and the continuous progress made in precision medicine, clinical guidance for gene classification and pan-cancer precision medicine may be made available to achieve real individualised medical care.
“It is our hope that the CTONG-OrigiMed platform can unite Chinese and foreign experts to develop more effective precision medicine clinical trials and solutions in fighting against cancer.”
The platform has been unveiled at a summit organised by OrigiMed and sponsored by the Chinese Thoracic Oncology Group (CTONG) and the International Cholangiocarcinoma Research Network (ICRN).
Involving more than 300 experts, the summit focused on immunotherapy, targeted therapy and precision medicine.
During the discussion, OrigiMed announced various new discoveries for cancer patients in China, including immunotherapy dataset, gene fusions distribution, Dr Groundhog Big Data Platform, along with a NGS lung cancer and breast cancer medical insurance upgrading project.
Combination of the new discoveries with clinical cases is expected to help guide clinical treatment.
According to the China National Cancer Center data, the country has the highest new cancer cases in the world. More than 4.2 million people are being newly diagnosed with the disease each year.